Intervention not reported
Quality of life (QoL) Inflammatory Bowel Disease Questionnaire (IBDQ) (scale: 32 to 224; higher score = better QoL) · Patients with active Crohn's disease
1 finding from 1 review
Withdrawal due to disease worsening · Patients with active Crohn's disease
Budesonide 15 mg probably leads to lower withdrawal due to disease worsening compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawal due to disease worsening · Patients with active Crohn's disease
It is very uncertain whether budesonide 9 mg changes withdrawal due to disease worsening compared with conventional steroids (very low certainty).
1 finding from 1 review
Withdrawal due to disease worsening · Patients with active Crohn's disease
Budesonide 9 mg probably leads to lower withdrawal due to disease worsening compared with mesalamine (moderate certainty).
1 finding from 1 review
Withdrawal due to disease worsening · Patients with active Crohn's disease
Budesonide 3 mg showed no clear difference in withdrawal due to disease worsening compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawal due to disease worsening · Patients with active Crohn's disease
Budesonide 9 mg showed no clear difference in withdrawal due to disease worsening compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Case control ‐ Crohn's disease, MMR · children 9 months to 15 years old
The intervention probably leads to lower case control ‐ Crohn's disease, MMR (moderate certainty).
1 finding from 1 review
Clinical relapse · patients with Crohn's disease (mixed disease activity population with clinical response at baseline)
Infliximab probably leads to lower clinical relapse (at 30‐32 weeks, CDAI > 150) compared with placebo (moderate certainty).
1 finding from 1 review
Loss of clinical response · Participants with Crohn's disease in remission
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · Participants with Crohn's disease in remission
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (at 2 years) · Participants with Crohn's disease in remission
It is very uncertain whether infliximab changes serious adverse events (at 2 years) compared with purine analogues (very low certainty).
1 finding from 1 review
Clinical relapse · patients with Crohn's disease (with mixed/low disease activity at baseline)
Infliximab showed no clear difference in clinical relapse (at 52 weeks, HBI > 4) compared with biosimilar (low certainty).
1 finding from 1 review
Loss of clinical response (at 52 weeks, HBI change from baseline of less than 4 points and a total score of less than 7 points) · patients with Crohn's disease (with mixed/low disease activity at baseline)
Infliximab may leads to higher loss of clinical response (at 52 weeks, HBI change from baseline of… compared with biosimilar (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with Crohn's disease (with mixed/low disease activity at baseline)
Infliximab may leads to higher withdrawal due to adverse events (at 52 weeks) compared with biosimilar (low certainty).
1 finding from 1 review
Serious adverse events (at 52 weeks) · patients with Crohn's disease (with mixed/low disease activity at baseline)
Infliximab showed no clear difference in serious adverse events (at 52 weeks) compared with biosimilar (low certainty).
1 finding from 1 review
Clinical relapse · patients with Crohn's disease (active disease population with clinical response at baseline)
It is very uncertain whether subcutaneous CT‐P13 and purine analogues changes clinical relapse (at 22 weeks, CDAI > 150) compared with intravenous CT‐P13 and purine analogues (very low certainty).
1 finding from 1 review
Loss of clinical response (at 22 weeks, less than 100 points in CDAI change) · patients with Crohn's disease (active disease population with clinical response at baseline)
It is very uncertain whether subcutaneous CT‐P13 and purine analogues changes loss of clinical response (at 22 weeks, less than 100 points in CDAI… compared with intravenous CT‐P13 and purine analogues (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with Crohn's disease (active disease population with clinical response at baseline)
It is very uncertain whether subcutaneous CT‐P13 and purine analogues changes withdrawal due to adverse events (at 30 weeks) compared with intravenous CT‐P13 and purine analogues (very low certainty).
1 finding from 1 review
Loss of clinical response (at 22 weeks, less than 100 points in CDAI change) · patients with Crohn's disease (mixed disease activity population with clinical response at baseline)
It is very uncertain whether infliximab changes loss of clinical response (at 32 weeks, less than 70 points in CDAI… compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events · patients with Crohn's disease (active disease population with clinical response at baseline)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found